GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innoviva Inc (NAS:INVA) » Definitions » Degree of Operating Leverage

INVA (Innoviva) Degree of Operating Leverage : -5.97 (As of Mar. 2025)


View and export this data going back to 2004. Start your Free Trial

What is Innoviva Degree of Operating Leverage?

Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue. Innoviva's Degree of Operating Leverage for the quarter that ended in Mar. 2025 was -5.97. The higher Degree of Operating Leverage, the higher operating risk the company will take.

The industry rank for Innoviva's Degree of Operating Leverage or its related term are showing as below:

INVA's Degree of Operating Leverage is ranked better than
88.99% of 881 companies
in the Biotechnology industry
Industry Median: -0.02 vs INVA: -5.97

Innoviva Degree of Operating Leverage Historical Data

The historical data trend for Innoviva's Degree of Operating Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innoviva Degree of Operating Leverage Chart

Innoviva Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Degree of Operating Leverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.66 1.51 2.25 4.69 -4.64

Innoviva Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Degree of Operating Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.28 -2.82 0.65 -4.64 -5.97

Competitive Comparison of Innoviva's Degree of Operating Leverage

For the Biotechnology subindustry, Innoviva's Degree of Operating Leverage, along with its competitors' market caps and Degree of Operating Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Innoviva's Degree of Operating Leverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innoviva's Degree of Operating Leverage distribution charts can be found below:

* The bar in red indicates where Innoviva's Degree of Operating Leverage falls into.


;
;

Innoviva Degree of Operating Leverage Calculation

Innoviva's Degree of Operating Leverage for the quarter that ended in Mar. 2025 is calculated as:

Degree of Operating Leverage=% Change in EBIT**/% Change in Revenue
=( -25.256 (Mar. 2025) / 218.663 (Mar. 2024) - 1 )/( 369.844 (Mar. 2025) / 311.59 (Mar. 2024) - 1 )
=-1.1155/0.187
=-5.97***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EBIT and Revenue was used to calculate Degree of Operating Leverage.
*** Please be aware that the Degree of Operating Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Innoviva  (NAS:INVA) Degree of Operating Leverage Explanation

Degree of Operating Leverage (DOL) is a leverage ratio that measures the sensitivity of a company’s operting income, also referred to as Earnings Before Interest and Taxes (EBIT), to fluctuations in its Revenue. DOL is a method used to quantify a company’s operating risk. This risk is related to the company's structure of variable costs and fixed costs. Since the fixed costs do not allow the company to adjust the operating costs, the operating risk rises with a higher fixed-to-variable costs proportion.

A high Degree of Operating Leverage indicates that the company’s fixed costs exceed its variable costs. By increasing the sales, the company can earn more profits. In addition, the company must be able to maintain relatively high sales to cover all fixed costs.

Be Aware

The use of operating leverage varies across different industries and business sectors, and the application of Degree of Operating Leverage (DOL) should be adjusted accordingly.


Innoviva Degree of Operating Leverage Related Terms

Thank you for viewing the detailed overview of Innoviva's Degree of Operating Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Innoviva Business Description

Industry
Traded in Other Exchanges
N/A
Address
1350 Old Bayshore Highway, Suite 400, Burlingame, CA, USA, 94010
Innoviva Inc is a company with a portfolio of royalties healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.
Executives
Alexander J Denner 10 percent owner C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Marianne Zhen officer: Chief Accounting Officer C/O INNOVIVA, INC., 2000 SIERRA POINT PARKWAY, SUITE 500, BRISBANE CA 94005
Stephen Basso officer: Chief Financial Officer C/O INOZYME PHARMA, INC., 321 SUMMER STREET, SUITE 400, BOSTON MA 02210
Margaret Koziel officer: Chief Medical Officer C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Deborah Birx director 3300 LOWELL STREET NW, WASHINGTON DC 20008
Sarissa Capital Management Lp 10 percent owner 660 STEAMBOAT ROAD, GREENWICH CT 06830
Pavel Raifeld officer: Chief Executive Officer 1350 OLD BAYSHORE HIGHWAY, SUITE 400, BURLINGAME CA 94010
Sapna Srivastava director C/O MYOS CORPORATION, 45 HORSEHILL ROAD, SUITE 106, CEDAR KNOLLS NJ 07927
Larry G. Edwards officer: CEO of La Jolla Pharmaceutical C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472
Plc Glaxosmithkline 10 percent owner 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS
Mark Dipaolo director 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Kostas D Odysseas director 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Sarah J. Schlesinger director C/O ARIAD PHARMACEUTICALS, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Jules Haimovitz director 601 108TH AVENUE NE, SUITE 1200, BELLEVUE WA 98004
George Bickerstaff director C/O VION PHARMACEUTICALS, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511